<DOC>
	<DOCNO>NCT01305551</DOCNO>
	<brief_summary>The purpose study demonstrate bioequivalence ( BE ) Saxagliptin Metformin 5 mg Saxagliptin/500 mg Metformin extend release ( XR ) fix dose combination ( FDC ) tablet relative 5 mg Onglyza™ 500 mg Glifage® XR ( market Brazil Merck S.A. ) tablet administer together fast fed state .</brief_summary>
	<brief_title>BE Study Fixed Dose Combination 5 mg Saxagliptin 500 mg Metformin HCl XR Tablet Relative 5 mg Saxagliptin ( Onglyza™ ) Tablet 500 mg Metformin HCl XR ( Glifage® XR Marketed Brazil Merck S.A. ) Tablet Co-Administered Healthy Subjects Fasted Fed States</brief_title>
	<detailed_description>Primary purpose : To demonstrate bioequivalence Saxagliptin Metformin 5 mg Saxagliptin/500 mg Metformin XR FDC tablet relative 5 mg Onglyza™ 500 mg Glifage® XR ( market Brazil Merck S.A. ) tablet administer together fast fed state .</detailed_description>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy men woman Women childbearing potential ( WOCBP ) use acceptable method contraception Women nurse History Gastrointestinal ( GI ) disease Any GI surgery could impact study drug absorption History allergy drug class related compound History allergy metformin similar act agent . History significant drug allergy . Estimated creatinine clearance ( ClCr ) &lt; 80 mL/min use CockcroftGault formula</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>